US2017072050A1PendingUtilityA1

Method for Inducing a TRIF-Bias

Assignee: GLAXOSMITHKLINE BIOLOGICALS SAPriority: Dec 23, 2008Filed: Apr 20, 2016Published: Mar 16, 2017

Est. expiryDec 23, 2028(~2.5 yrs left)· nominal 20-yr term from priority

Inventors:William S. Bowen Jay Evans Melinda M. Hutton David A. Johnson Laurie A. Minns

A61P 37/04A61P 43/00A61P 29/00A61P 25/00A61P 1/00A61K 2039/55572A61P 19/02A61K 39/39A61K 31/665A61K 45/06A61K 31/661

PatentIndex Score

Cited by

References

Claims

Abstract

Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF-biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.

Claims

exact text as granted — not AI-modified

1 . A lipid A mimetic composition comprising CRX547 for use in raising an immune response in a human wherein TRIF-dependent cytokines are increased and MyD88-dependent cytokines and decreased compared to a lipid A mimetic composition in the absence of CRX547. 
     
     
         2 . A lipid A mimetic composition comprising CRX547 for use in raising an immune response in a human wherein NF-κB activity is decreased, but equal or higher levels of IRF3 are observed compared to a lipid A mimetic composition in the absence of CRX547. 
     
     
         3 . A lipid A mimetic composition comprising CRX547 for use in raising an immune response in a human wherein IL-12p70 and IL-23 levels are decreased compared to a lipid A mimetic composition in the absence of CRX547.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.